Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04305691 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trial of Ixazomib for Kaposi Sarcoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 10 to 11v20
  2. Re-verified, no change to tracked fieldsv19
  3. Study sites: 9 to 10v18
  4. Study sites: 8 to 9v17
  5. Primary completion date: May 31, 2025 to Mar 15, 2029
    • Study sites: 7 to 8
    • Study completion date: May 30, 2026 to Mar 15, 2029
    v16
Show 14 earlier versionsHide 14 earlier versions
  1. Study sites: 6 to 7v15
  2. Re-verified, no change to tracked fieldsv14
  3. Study sites: 4 to 6v13
  4. Study sites: 3 to 4v12
  5. Study sites: 2 to 3v11
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 20, 2023 to Nov 7, 2023
    • Site details revised at 2 of 2 sites
    v10
  7. Study sites revised (2)v9
  8. Study completion date: May 31, 2027 to May 30, 2026v8
  9. Trial status: Suspended to Not Yet Recruitingv7 Show 4 more changesShow less
    • Primary completion date: May 31, 2024 to May 31, 2025
    • Start date: Nov 20, 2020 to Nov 20, 2023
    • Study completion date: May 31, 2025 to May 31, 2027
    • Site contacts updated at 2 of 2 sites
  10. Eligibility criteria expanded, about 251 words
    • Study sites revised (2)
    v6
  11. Trial status: Recruiting to Suspended Sponsor's reason: Transferring drug supplier from Takeda to NCI CTEP.
    • Site details revised at 2 of 2 sites
    v5
  12. Study sites: 1 to 2v4
  13. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 21, 2020 to Nov 20, 2020
    • Site details revised
    v3
  14. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies how well ixazomib works in treating patients with Kaposi sarcoma. Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Trial Details
NCT Number NCT04305691
Lead Sponsor AIDS Malignancy Consortium
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Kaposi Sarcoma, Skin
Related terms Sarcoma, Kaposi
Enrollment 41 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov